Afamelanotide
Scenesse · Melanotan I Analog
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
Afamelanotide is a genuinely FDA-approved (October 2019) and EMA-authorised (December 2014) drug for the narrow rare-disease indication of erythropoietic protoporphyria, so the approved use rests on real regulatory review rather than the anecdotal base of most research peptides. The evidence is graded grade 4 rather than grade 5 because approval rested on a modest set of randomised trials (the pivotal package spanned three trials in roughly 244 adults, anchored by Langendonk et al., NEJM 2015) with a subjective, patient-reported pain-free sunlight-exposure endpoint and a small orphan population, which is strong for the indication but short of the overwhelming, decades-wide consensus that grade 5 implies. The illegal gray-market tanning use of Melanotan I is a separate, unapproved application and carries none of this evidence.
- FDA
- FDA Approved October 2019 (Scenesse, 16mg implant, EPP phototoxicity); EMA authorised December 2014
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Approved only for erythropoietic protoporphyria as a physician-implanted depot; the injectable Melanotan I sold for tanning is an unapproved, illegal gray-market use with no approved safety oversight.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Afamelanotide. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
An FDA-approved alpha-MSH analog for erythropoietic protoporphyria, a rare disorder of extreme sun sensitivity. Distinct from and far less risky than Melanotan II.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Erythropoietic protoporphyria / EPP (Scenesse)
- FDA-approved in 2019, and in Europe in 2014, to increase pain-free light exposure in adults with this ultra-rare inherited disorder that makes sunlight cause excruciating skin pain. It was the first approved treatment for EPP, granted orphan-drug and priority-review status, and is given as a clinician-inserted implant every two months. There is no approved cosmetic tanning indication.
How it works
Afamelanotide switches on the melanocortin-1 receptor (MC1R) on pigment cells, telling the skin to make more eumelanin, the protective form of melanin, without any sunlight or UV. That matters because eumelanin absorbs and scatters UV, scavenges free radicals and shields the skin, and MC1R signaling also boosts antioxidant defenses, DNA repair and anti-inflammatory activity. So it darkens and protects the skin through the body’s own pigment pathway, but triggered by the drug rather than by sun damage, which is exactly what people with a severe light-sensitivity disorder need.
Afamelanotide is a synthetic tridecapeptide, 13 amino acids, a structural analog of alpha-MSH, the natural melanocyte-stimulating hormone, differing at two positions to give it a longer half-life. It is the linear molecule known as Melanotan-I, distinct from the cyclic gray-market Melanotan-II. Sold under the brand name Scenesse by Clinuvel, it is delivered as a controlled-release implant rather than an injection.
- Type
- MC1R agonist (alpha-MSH analog)
- Effect
- Eumelanin without UV
- Form
- Controlled-release implant
- Approved
- EPP (Scenesse, 2019)
- Half-life
- ~15 hours
- Tanning use
- Not approved
The Approved Melanocortin, Not The Tanning One
Afamelanotide is the genuinely FDA-approved melanocortin, and that distinction is the whole point. As Scenesse, it is approved, by the FDA in 2019 and in Europe since 2014, to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), an ultra-rare inherited disorder that makes sunlight excruciating. It was the first approved treatment for that condition, backed by randomized controlled trials and published in the New England Journal of Medicine, and it is administered as a clinician-inserted implant every two months, not a casual injection. The honest and important contrast is what it is not: this is not the Melanotan sold online for cosmetic tanning. Afamelanotide is the same molecule as gray-market Melanotan-I, but the approved product is regulated, tested and reserved for a specific rare disease, with no approved cosmetic tanning indication, while the online tanning peptides, both Melanotan-I and the cyclic Melanotan-II, are unapproved, untested compounded or research-grade material. Same receptor family, opposite worlds.
Safety in detail
The approved product is a controlled 16mg subcutaneous implant placed by a clinician every two months, a fundamentally different exposure than self-injected gray-market Melanotan I. Reported label adverse effects include implant-site reactions, nausea, headache, and fatigue; because the drug darkens skin, dermatological monitoring for pigmented lesions is advised.
- Common effects include implant-site reactions, nausea, fatigue and skin darkening, which is the intended mechanism.
- Because it stimulates pigment cells, it can produce or change moles, so twice-yearly full-body skin exams are recommended.
- Serious hypersensitivity reactions, including anaphylaxis, have been reported after marketing.
- It is administered as a clinician-inserted implant in a controlled medical setting, and the approved product is tested and regulated.
- This stands in sharp contrast to gray-market Melanotan tanning peptides, which are unapproved and untested.
Children and teenagers
Scenesse is approved for adults with EPP; its trials were in adults, and its use is adult. While EPP can appear in childhood, afamelanotide’s approval and administration are adult and specialist-managed. Separately, the gray-market Melanotan tanning peptides, with their pigment and mole risks, have no place in minors. Any pediatric EPP care belongs with specialists, and cosmetic tanning use is inappropriate for minors entirely.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Afamelanotide’s legitimate economy is Clinuvel’s, which markets Scenesse as a regulated orphan drug for a tiny rare-disease population, priced as an expensive specialty therapy and administered through specialist centers. Entirely separate is the gray-market Melanotan tanning economy, unapproved peptides sold online for cosmetic tanning that have nothing to do with Clinuvel or the approved product. The two are often conflated, but only one is a tested, approved medicine.
How we got here
Afamelanotide began as Melanotan-I, a potentiated alpha-MSH analog synthesised at the University of Arizona in the 1980s by Mac Hadley, Victor Hruby, and colleagues, who introduced the Nle4 and D-Phe7 substitutions to slow degradation and boost melanocortin-1 receptor activity. The molecule was named for its ability to tan skin with minimal sun exposure, and its rights were held by Competitive Technologies as the University of Arizona technology-transfer agent, which licensed it to the Australian startup Epitan. Epitan renamed itself Clinuvel in 2006, dropped the cosmetic tanning ambition in favour of the rare-disease indication, and developed a controlled-release implant to overcome the peptide's short half-life, ultimately bringing it to market as Scenesse (EMA 2014, FDA 2019). The same molecule persists on the illegal gray market as injectable Melanotan I sold for tanning, which is unapproved and separate from the licensed EPP implant.
Afamelanotide grew out of the melanocortin and Melanotan research of the 1980s, as the linear alpha-MSH analog Melanotan-I. Clinuvel developed it specifically for photoprotection, running randomized controlled trials in erythropoietic protoporphyria, and it was approved in Europe in 2014 and by the FDA in 2019 as the first treatment for EPP. In parallel, and entirely outside this regulated path, gray-market Melanotan-I and the cyclic Melanotan-II spread online for cosmetic tanning, unapproved and untested, creating a lasting confusion between a rigorous rare-disease drug and an unregulated tanning shortcut.
- 1980sMelanocortin and Melanotan research produces the alpha-MSH analogs.
- 2010sClinuvel runs randomized controlled trials of afamelanotide in EPP.
- 2014The European Medicines Agency approves afamelanotide for EPP.
- 2019The FDA approves Scenesse as the first treatment for EPP.
- ongoingGray-market Melanotan tanning peptides persist separately, unapproved.
The numbers behind the grade
- Type
- MC1R agonist (13 aa)
- Brand
- Scenesse
- Approved
- EPP (2019)
- Form
- Implant
- Evidence
- RCT-backed
- Tanning drug
- No
The people taking it
The genuinely FDA-approved melanocortin, a rare-disease photoprotection drug, and the evidence-anchored, regulated counterpart to the gray-market Melanotan tanning peptides it is often confused with.
Afamelanotide’s approved users are the small population of adults with erythropoietic protoporphyria, treated at specialist centers, an ultra-rare group affecting roughly one in 100,000. This is entirely distinct from the cosmetic-tanning crowd that buys unapproved Melanotan peptides online; the approved drug is not for them and is not marketed for tanning.
Approved in the US and Europe for erythropoietic protoporphyria, administered as a clinician-inserted implant for photoprotection. The separate gray-market Melanotan tanning peptides are unapproved and are not this drug.
Set against the alternatives
Against Melanotan-II, the cyclic gray-market cousin used for tanning and libido, afamelanotide is the approved, MC1R-focused, regulated counterpart, where Melanotan-II is unapproved, broad-acting and linked to risks like priapism. Against gray-market Melanotan-I, the comparison is striking because it is the same molecule, yet the online tanning version is compounded or research-grade material, not the tested, approved Scenesse. And against PT-141, the other approved melanocortin, the two show the pattern: PT-141 targets the MC4R receptor for sexual desire, afamelanotide targets MC1R for photoprotection, and both earned approval through narrow, tested indications, unlike the gray-market tanning peptides. Its strength is being a properly approved melanocortin; the lesson is how different that is from its unregulated relatives.
What we do not know
- Whether afamelanotide gains approval for other photodermatoses or pigment conditions being studied.
- How best to monitor skin and moles over long-term use.
- How the broader melanocortin-photoprotection field develops.
- How to curb the ongoing public-health problem of unapproved Melanotan tanning use.
What could change
Additional indicationsResearch explores afamelanotide for other photodermatoses and pigment conditions.Long-term monitoringOngoing attention to skin and mole surveillance during treatment.Melanocortin photoprotectionThe broader field of pigment-based protection continues to develop.Gray-market confusionThe persistent challenge of unapproved Melanotan tanning use.
Legal status
Afamelanotide is FDA-approved as Scenesse (2019, and in Europe since 2014) for adults with EPP, administered as a clinician-inserted implant every two months. There is no approved cosmetic tanning indication. The Melanotan tanning peptides sold online are a separate, unapproved category, compounded or research-grade, and are not the approved product.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Afamelanotide is obtained only through specialist prescription and clinician implantation for EPP; it is not sold for cosmetic tanning. The online Melanotan tanning products are unapproved, untested, and a different, riskier thing entirely, and should not be confused with the approved drug.
Scenesse is an expensive orphan-drug specialty therapy, reflecting its rare-disease indication and clinician administration. The gray-market Melanotan tanning peptides are cheap by comparison, but they are unapproved and untested, so the price gap reflects a fundamental difference in what is being bought.
The approved drug comes solely from Clinuvel under full regulation, administered by trained clinicians. Gray-market Melanotan tanning peptides come from unapproved Chinese or compounded sources and are not the approved product.
Clinuvel (approved)Manufactures Scenesse as a regulated implant, administered by trained clinicians at specialist centers.Separate gray-marketOnline Melanotan tanning peptides are an unapproved, compounded or research-grade supply, not the approved drug.Specialist administrationThe approved product requires clinician implantation, unlike self-injected gray-market peptides.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Afamelanotide.
Nothing outstanding on this one.
Sources
FDA approved Scenesse (afamelanotide) in October 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria; first medication approved for EPP, granted priority review and orphan designation
FDA risk review document for NDA 210797 (afamelanotide / Scenesse), 2019 approval package
EMA authorised Scenesse (afamelanotide) on 22 December 2014 for prevention of phototoxicity in adult patients with erythropoietic protoporphyria; delivered as a 16mg subcutaneous implant administered once every two months
Afamelanotide received EU orphan designation for erythropoietic protoporphyria on 8 May 2008 (EU/3/08/541); withdrawn from the orphan register in December 2024 at the end of the 10-year market exclusivity period
Pivotal randomised controlled trial: EPP patients on afamelanotide accumulated a median 64 pain-free hours in direct sunlight over 180 days versus 41 hours on placebo; a separate arm reported 69.4 versus 40.8 hours
Afamelanotide (Scenesse; also CUV1647, NDP-MSH, NDP-alpha-MSH, [Nle4,D-Phe7]-alpha-MSH, Melanotan I) is a synthetic 13-amino-acid analog of alpha-MSH; developed at the University of Arizona in the 1980s by Hadley and Hruby, licensed via Competitive Technologies to Epitan, which became Clinuvel in 2006
FDA approval based on data from clinical trials totalling 244 adults across 22 sites; afamelanotide increases eumelanin production independently of UV exposure; first EPP therapy approved in the United States
HCPLive, FDA Approves Afamelanotide to Treat Erythropoietic Protoporphyria
Melanotan I (afamelanotide) is the MC1R-focused approved analog, distinct from the unapproved Melanotan II sold on the tanning gray market; clinical evidence and safety profile overview
Pharmacy Times, FDA Approves New Treatment for Erythropoietic Protoporphyria
Payer clinical policy summarising Scenesse indication, dosing (one 16mg implant subcutaneously every 2 months), and coverage criteria for erythropoietic protoporphyria
Aetna Clinical Policy Bulletin 0962, Afamelanotide (Scenesse)
Melanotan-I was licensed from the University of Arizona through Competitive Technologies to the Australian startup Epitan, which renamed to Clinuvel in 2006 and brought the drug to market as Scenesse; the compound was initially pursued as a sunless tanning agent
The studies that matter
Vehicle-controlled EPP trials2010s
Three randomized, vehicle-controlled trials in 244 adults with EPP showed afamelanotide meaningfully increased pain-free time in direct sunlight versus placebo.
NEJM publication2015
The pivotal EPP trial results were published in the New England Journal of Medicine, establishing the evidence base.
European approval2014
The European Medicines Agency approved afamelanotide for EPP, ahead of the US.
FDA approval2019
The FDA approved Scenesse as the first treatment for EPP, with orphan-drug and priority-review designations.
Liver-protection signal2020s
Afamelanotide was associated with a dose-dependent protective effect against EPP-related liver damage.